Fiche société
jiangjingting
Traitements, essais et publications liés.
Traitements3programmes
Essais1liés
Publications0liées
SourceDBlocale
Traitements
3| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| IL-2 pre-treated CD19 cellsThis study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. | SEP | Phase 4 | Immunomodulation | China | À vérifier |
| IL-7/IL-15 pre-treated CD19 cellsThis study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. | SEP | Phase 4 | Immunomodulation | China | À vérifier |
| IL-2 pre-treated CD19 cellsThis study aims to evaluate the safety, efficacy and duration of response of CD19 Chimeric Antigen Receptor (CAR) redirected allogeneic T-cells in patients with chemotherapy-resistant or refractory CD19+ B cell lymphoma. | SEP | Phase 4 | Immunomodulation | China | À vérifier |
Essais cliniques
1| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| IL-2 pre-treated CD19 cells | SEP | Phase 4 | NCT02992834 | Anti-CD19:TCRζ Chimeric Antigen Receptor-T Cells in the Treatment for CD19+ B Cell Lymphoma | UNKNOWN |
Publications
0| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| Aucune publication. | ||||